U.S. Markets open in 4 hrs 31 mins

Palatin Technologies, Inc. (PTN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4412-0.0087 (-1.93%)
At close: 4:00PM EST

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
http://www.palatin.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. John K. A. PrendergastCo-Founder & Independent Non-Exec. Chairman97.5kN/A1954
Dr. Carl SpanaCo-Founder, Pres, CEO & Director867.62kN/A1962
Mr. Stephen T. Wills CPA, CPA, MSTCFO, COO, Exec. VP, Treasurer & Sec.797.21kN/A1957
Burns McClellanVP of Investor RelationsN/AN/AN/A
Mr. Stephen A. Slusher Esq.Chief Legal OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.

Corporate Governance

Palatin Technologies, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 4. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.